Bone Mineral Density in Diabetes Mellitus Foot Patients for Prediction of Diabetic Neuropathic Osteoarthropathic Fracture
2
조회
0
다운로드
0
인용
0
참고문헌
초록
Background: Diabetic neuropathic osteoarthropathy (DNOAP) is known as debilitating diabetes complications. The aim of study is to compare bone mineral density (BMD) among diabetic foot and DNOAP, and investigate the impact of BMD proceeded from diabetic foot to DNOAP. Methods: A DNOAP group (subgroup A and subgroup B) and control group were examined for this study. Subgroup A (n=21) were patients diagnosed with DNOAP with the development of new foot and ankle fractures, whereas subgroup B (n=4) were patients being managed with the diabetic foot before a diagnosis of DNOAP. BMD was also evaluated before the diagnosis. Control group (n=30) was diabetic foot patients without DNOAP. The demographic data, clinical and radiologic data, comorbidities, and BMD were compared for each group. And optimal BMD score was reviewed to predict fractures in neuropathic arthropathy. Results: BMD was significantly lower in DNOAP group (group A and B) compared with control group. Also neuropathic arthropathy group showed poor radiological results. After comparisons of 2 group lumbar and femur BMD was significantly different, but logistic regression analysis revealed that low femur T-score could be risk predictors of the condition. Base on the data of group B and control group, the cut-off point for predicting foot and ankle fracture-related with DNOAP was -1.65 of femur BMD. Conclusions: Low BMD shows greater incidence in foot and ankle fracture patients associated with neuropathic arthropathy. A femur T score can be a risk predictor of diabetic neuropathic arthropathy for diabetic foot patients.
Abstract
Background: Diabetic neuropathic osteoarthropathy (DNOAP) is known as debilitating diabetes complications. The aim of study is to compare bone mineral density (BMD) among diabetic foot and DNOAP, and investigate the impact of BMD proceeded from diabetic foot to DNOAP. Methods: A DNOAP group (subgroup A and subgroup B) and control group were examined for this study. Subgroup A (n=21) were patients diagnosed with DNOAP with the development of new foot and ankle fractures, whereas subgroup B (n=4) were patients being managed with the diabetic foot before a diagnosis of DNOAP. BMD was also evaluated before the diagnosis. Control group (n=30) was diabetic foot patients without DNOAP. The demographic data, clinical and radiologic data, comorbidities, and BMD were compared for each group. And optimal BMD score was reviewed to predict fractures in neuropathic arthropathy. Results: BMD was significantly lower in DNOAP group (group A and B) compared with control group. Also neuropathic arthropathy group showed poor radiological results. After comparisons of 2 group lumbar and femur BMD was significantly different, but logistic regression analysis revealed that low femur T-score could be risk predictors of the condition. Base on the data of group B and control group, the cut-off point for predicting foot and ankle fracture-related with DNOAP was -1.65 of femur BMD. Conclusions: Low BMD shows greater incidence in foot and ankle fracture patients associated with neuropathic arthropathy. A femur T score can be a risk predictor of diabetic neuropathic arthropathy for diabetic foot patients.
참고문헌 (33)
- Charcot JM, "Sur quelques arthropathies qui paraissent dépendre d’une lésion du cerveau ou de la moëlle épinière", Arch Physiol Norm Path, 1, pp.161~178 (1868)
- Frykberg RG, "Management of the diabetic Charcot foot", Diabetes Metab Res Rev, 16(Suppl 1), pp.S59~S65 (2000)
- Jordan WR, "Neuritic manifestations in diabetes mellitus", Arch Intern Med, 57, pp.307~366 (1936)
- Young MJ, "Osteopenia, neurological dysfunction, and the development of Charcot neuroarthropathy", Diabetes Care, 18, pp.34~38 (1995)
- Hastings MK, "Bone mineral density during total contact cast immobilization for a patient with neuropathic(Charcot)arthropathy", Phys Ther, 85, pp.249~256 (2005)
- Jackuliak P, "Osteoporosis, fractures, and diabetes", Int J Endocrinol, 2014, pp.820615~ (2014)
- Clasen S., "Is diabetic Charcot foot related to lower limb osteopaenia?", Foot Ankle Surg, 6 (2000)
- Kaynak G, "An overview of the Charcot foot pathophysiology", Diabet Foot Ankle, 4 (2013)
- Gouveri E, "Charcot osteoarthropathy in diabetes : A brief review with an emphasis on clinical practice", World J Diabetes, 2, pp.59~65 (2011)
- Jirkovská A, "Calcaneal ultrasonometry in patients with Charcot osteoarthropathy and its relationship with densitometry in the lumbar spine and femoral neck and with markers of bone turnover", Diabet Med, 18, pp.495~500 (2001)
- Beeve AT, "Peripheral Neuropathy as a Component of Skeletal Disease in Diabetes", Curr Osteoporos Rep, 17, pp.256~269 (2019)
- Rathinavelu S, "Molecular Modulation of Osteoblasts and Osteoclasts in Type 2 Diabetes", J Diabetes Res, 2018, pp.6354787~ (2018)
- Jeffcoate WJ, "The role of proinflammatory cytokines in the cause of neuropathic osteoarthropathy(acute Charcot foot)in diabetes", Lancet, 366, pp.2058~2061 (2005)
- Herbst SA, "Pattern of diabetic neuropathic arthropathy associated with the peripheral bone mineral density", J Bone Joint Surg Br, 86, pp.378~383 (2004)
- SooHoo NF, "Responsiveness of the foot function index, AOFAS clinical rating systems, and SF-36 after foot and ankle surgery", Foot Ankle Int, 27, pp.930~934 (2006)
- Kanis JA, "Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: synopsis of a WHO report. WHO Study Group", Osteoporos Int, 4, pp.368~381 (1994), WHO Study Group
- Hofbauer LC, "Osteoporosis in patients with diabetes mellitus", J Bone Miner Res, 22, pp.1317~1328 (2007)
- Christensen TM, "Bone mineral density in diabetes mellitus patients with and without a Charcot foot", Clin Physiol Funct Imaging, 30, pp.130~134 (2010)
- Jansen RB, "Bone mineral density and markers of bone turnover and inflammation in diabetes patients with or without a Charcot foot: an 8.5-year prospective case-control study", J Diabetes Complications, 32, pp.164~170 (2018)
- Petrova NL, "Calcaneal bone mineral density in patients with Charcot neuropathic osteoarthropathy : differences between Type 1 and Type 2 diabetes", Diabet Med, 22, pp.756~761 (2005)
- Mascarenhas JV, "Pathogenesis and medical management of diabetic Charcot neuroarthropathy", Med Clin North Am, 97, pp.857~872 (2013)
- Trieb K., "The Charcot foot: pathophysiology, diagnosis and classification", Bone Joint J, 98-b, pp.1155~1159 (2016)
- Fauzi AA, "Risk factors of diabetic foot Charcot arthropathy : a case-control study at a Malaysian tertiary care centre", Singapore Med J, 57, pp.198~203 (2016)
- Nóbrega MB, "Risk factors for Charcot foot", Arch Endocrinol Metab, 59, pp.226~230 (2015)
- Hartemann-Heurtier A, "The Charcot foot", Lancet, 360, pp.1776~1779 (2002)
- Nehring P, "Risk factors of charcot neuroarthropathy development in patients with type 2 diabetes", Exp Clin Endocrinol Diabetes, 122, pp.31~34 (2014)
- Pakarinen TK, "Charcot arthropathy of the diabetic foot. Current concepts and review of 36 cases", Scand J Surg, 91, pp.195~201 (2002)
- Stuck RM, "Charcot arthropathy risk elevation in the obese diabetic population", Am J Med, 121, pp.1008~1014 (2008)
- Foltz KD, "Usefulness of a brief assessment battery for early detection of Charcot foot deformity in patients with diabetes", J Foot Ankle Surg, 43, pp.87~92 (2004)
- Jones J, "Neuropathic shoulder arthropathy(Charcot joint)associated with syringomyelia", Neurology, 50, pp.825~827 (1998)
- Sinacore DR, "Inflammatory osteolysis in diabetic neuropathic(charcot)arthropathies of the foot", Phys Ther, 88, pp.1399~1407 (2008)
- El Oraby HA, "Bone mineral density in type 2 diabetes patients with Charcot arthropathy", Curr Diabetes Rev, 15, pp.395~401 (2019)
- 박소영, "Korean Guideline for the Prevention and Treatment of Glucocorticoid-induced Osteoporosis", 대한골대사학회지, 25(4), pp.195~211 (2018), 대한골대사학회